TrialNature medicine2021

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.

Roberto A Calle et al.PubMed ↗Publisher ↗

No numbers read from the abstract.